Value proposition development for a phase 3 neuroscience asset

• Life Sciences
• Reports

When innovation outpaces access: Closing the gap in chronic lymphocytic leukemia care

New targeted therapies have extended survival, improved quality of life, and enabled more personalized treatment decisions based on genetic risk factors, age,...

• Life Sciences
• CRA Insights

CAR-T vs. bispecific therapies: Two growth stories are reshaping hematologic oncology

While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...

• Life Sciences
• Sponsorship & Speaking Engagement

• October 6-7, 2026
• Toronto, ON

25th Annual Market Access Summit

CRA is a proud sponsor of the event for market access, reimbursement, and government policy experts. Ashley Fraser presents on “MFN – Implications in...

• Antitrust & Competition
• Sponsorship & Speaking Engagement

• October 21, 2026
• New York, NY

GCR Live: Antitrust in Life Sciences

CRA is a proud sponsor of the event. Josh Sherman is a panelist during the session titled “Global antitrust trends reshaping the life sciences market”...